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Abstract
Glycation stress (glycative stress) is a general concept of biological stress caused 
by a series of non-enzymatic glycation reactions, including advanced glycation end 
products (AGEs) formation, AGEs accumulation, glycation-associated dysfunction 
of proteins and cellular signaling, inflammation, oxidation, and/or tissue dam-
age. There has been increasing evidence supporting a profound effect of AGEs on 
human diseases such as type 2 diabetes, cardiovascular disease, cancer, Alzheimer’s 
disease, osteoporosis, and dementia, as well as aging process itself. In addition, 
dietary AGEs intake has also been suggested to contribute to tissue dysfunction 
and development of the diseases. Skeletal muscle is the largest organ in the human 
body and important responsibility for maintaining our health as not only locomo-
tor system but also metabolic and endocrine systems. Especially in past decades, 
numerous studies have suggested the contribution of glycation stress to skeletal 
muscle dysfunctions (e.g. muscle atrophy, reducing contractile property, and insu-
lin resistance). In this chapter, we provide current evidence on the potential role of 
glycation stress in the impairment of skeletal muscle functions.
Keywords: glycative stress, skeletal muscle dysfunction, skeletal muscle atrophy, 
advanced glycation end products, AGEs
1. Introduction
Skeletal muscle is the largest organ in the human body, accounting for approxi-
mately 40% of body weight. A primary characteristic of skeletal muscle is its ability 
to contract and cause movement. In addition, skeletal muscle is a metabolic organ 
of high metabolic activity regarding nutrient (glucose, lipid, and protein) storage 
and supply. It has also recently been found that skeletal muscle is a secretary organ 
that produces and releases cytokines and other peptides, which is known as myo-
kine, that function in manner similar to hormones [1]. Thus, skeletal muscle has an 
important responsibility for maintaining our health as not only locomotor system 
but also metabolic and endocrine systems [2]. After the age of 50, approximately 
1–2% of muscle mass and 1.5–5% of muscle strength are lost per year [3]. These 
reductions in muscle mass, strength, and function, the so-called sarcopenia, link 
to numerous adverse consequences including frailty, disability, morbidity, and 
mortality [2].
Over the last few decades, there has been increasing evidence supporting a 
profound effect of advanced glycation end products (AGEs) on human diseases, 
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including type 2 diabetes, cardiovascular disease, cancer, Alzheimer’s disease, 
osteoporosis, and dementia, as well as the aging process itself [4, 5]. Especially in 
past decades, many epidemiological studies have suggested the contribution of 
glycation stress (also called as glycative stress) from AGEs to sarcopenia [6–17]. In 
this chapter, we provide current evidence on the potential role of glycation stress in 
the impairment of skeletal muscle functions.
2. Glycation stress
Glycation stress is a general concept of biological stress caused by a series of 
glycation reactions, including AGEs formation, AGEs accumulation, glycation-
associated dysfunction of proteins and cellular signaling, inflammation, oxidation, 
and/or tissue damage (Figure 1).
Protein glycation is a complex series of sequential reactions collectively called the 
Maillard reaction, which is named after the French chemist Louis Camilli Maillard. 
The Maillard reaction is divided into three stages, early (the formation of reversible 
Schiff base and rearrangement to Amadori products), intermediate (the forma-
tion of unstable AGEs precursors), and late (the formation of irreversible AGEs 
products). At the early stage, the carbonyl group of the reducing sugar reacts with 
the α-amino group at the N-terminal of protein or the ε-amino group of lysine or 
arginine residue, resulting in a formation of Schiff-base intermediates, followed by a 
rearrangement to Amadori products, relatively stable ketoamine. Amadori products 
in the living body include hemoglobin A1c and glycoalbumin. At the intermediate 
stage, the reaction proceeds and produces highly reactive dicarbonyl intermediates 
such as 3-deoxyglucosone and methylglyoxal. These intermediates are up to 20,000 
times more reactive than glucose in glycation reactions [18]. At the late stage, the 
intermediates undergo complex reactions such as oxidation, dehydration, condensa-
tion, and cleavage to form stable AGEs, with a variety of physicochemical character-
istics such as brown color, fluorescence, and cross-linking. Glycation of protein is a 
post-translational modification that progresses non-enzymatically, unlike enzymatic 
glycosylation, phosphorylation, acetylation, and glycosylation. Among more than 20 
types of AGEs identified in vivo, methylglyoxal-derived hydroimidazolone (MG-H1) 
and Nε-carboxymethyllysine (CML) are likely the most abundant [19, 20].
Intracellular protein glycation can cause changes in the protein structure due to 
covalent cross-linking, resulting in the formation of protein misfolding and aggre-
gation [21]. Although these unfunctional proteins are usually degraded through 
Figure 1. 
Conceptual diagram of glycation stress.
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ubiquitin-proteasome system, AGEs-modified protein is the lack of free lysine 
residue needed for ubiquitin conjugation, preventing protein ubiquitination and 
subsequent its degradation by proteasome [22]. In addition, enzymes present in the 
ubiquitin-proteasome system and lysosomal proteolytic system are also undergone 
glycation [23]. Thus, intracellular glycation disrupts proteostasis, inducing cell 
apoptosis, and thereby increasing the risk of disorders.
On the other hand, extracellular AGEs stimulate several signaling pathways 
by a series of cell surface receptors. The most studied of which is receptor for 
AGEs (RAGE), a multi-ligand member of the immunoglobulin superfamily [24]. 
The activation of AGEs-RAGE axis causes the onset of several diseases, including 
diabetic complications, cardiovascular disease, Alzheimer’s disease, and osteo-
porosis, by inducing inflammation and the production of reactive oxygen species 
[25–28]. RAGE is widely expressed in various cells and organs, can be upregulated 
under pathological conditions where AGEs are increased, and participate in those 
aging-related pathophysiologies [29]. On the other hand, other groups of cell-
surface receptors of AGEs with opposite functions to RAGE, including AGE-R1/
Oligosaccharyltransferase 48 KDa Subunit, AGE-R2/protein kinase C substrate 
80 K-H, and AGE-R3/galectin-3, and scavenger receptor families act as regulators of 
endocytosis and clearance of AGEs [30, 31]. These receptors can suppress AGEs-
RAGE interaction, but their expressions and functions are impaired during aging 
and under higher levels of oxidative stress [30]. There is an inverse relationship 
between AGE-R1 expression and AGEs toxicity [30].
3. Dietary AGEs
AGEs are not only produced endogenously; we ingested them from diet. AGEs 
content of food depends on the content of protein, fat, and sugar and the types of 
processing and cooking methods, predominantly on the temperature and dura-
tion of preparation [32]. High temperatures during various processes like baking, 
roasting, frying and grilling promote glycation in food. Scheijen et al. [33] analyzed 
the content of CML, Nε-carboxyethyllysine (CEL), MG-H1 in the protein fraction 
of the 190 food items by UPLC-MS/MS, and they showed that CML and CEL were 
contained in <7 mg/100 g in high-content foods such as fried bacon, chocolate, and 
peanut butter. The content of MG-H1 was higher compared to those of CML and 
CEL, and it was <65 mg/100 g in high-content foods such as black pudding, peanut 
butter, cereals, and biscuit.
Proteins are digested into amino acids and small peptide in the gastrointestinal 
tract. Therefore, dietary AGEs are expected to be absorbed in the circulation 
mostly in the form of free AGEs and AGEs-modified peptides. The amount of AGEs 
absorbed in the circulation was estimated to be 10% in healthy people; 1/3 of the 
absorbed AGEs are excreted in urine within 48 hours and 2/3 remained in the body 
[34]. For healthy people, a daily AGEs intake of around 9,000–23,000 kU/day was 
determined [32]; one AGE Unit was defined as the amount of antibody-reactive 
material that was equivalent to that in 1 μg of an AGEs-BSA standard. The AGEs 
content of major meals [35] is listed in Table 1.
A cross-sectional study revealed that higher levels of dietary AGEs were associ-
ated with higher levels of free plasma and urinary AGEs [36]. In addition, a tracer 
study using 13C2-CML found that dietary CML was accumulated in kidney, ileum, 
colon, lung, brain, testis, heart muscle, skeletal muscle, and liver, but not in fat [37], 
suggesting the contribution of dietary AGEs to tissue dysfunction and development 
of diseases. In fact, a meta-analysis of 13 randomized controlled trials showed a 
decrease in metabolic parameters including body weight, insulin resistance, total 
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cholesterol, low-density lipoprotein, and leptin and an increase in adiponectin levels 
after consumption of low AGEs diets compared to high AGEs diets [38, 39]. This 
study indicates that the restriction of AGEs from food can be effective in reducing 
the incidence of chronic metabolic diseases and promoting health.
4. The effect of AGEs on skeletal muscle
4.1 AGEs accumulation and skeletal muscle dysfunction
In this about 10 years, epidemiological studies have reported the relationship 
between AGEs level in the body and skeletal muscle functions. The first report by 
Meal AGEs kU/serving Calory kcal/serving
Carbonara spaghetti (280 g) 27,033 1,043
Sirloin steak (200 g) 26,843 1,003
Mixed pizza (1/2 piece) 21,783 1,211
Seafood pizza (1/2 piece) 19,676 1,211
Beef cutlet curry (450 g) 17,337 1,407
Hamburger steak (220 g) 11,170 453
Roasted dumplings (10 pieces) 8,668 627
Fried chicken (130 g) 7,997 532
Fried shrimp (245 g) 7,290 588
Deep-fried tofu (155 g) 6,063 204
Salt-grilled saury (130 g) 6,032 315
Hamburger (1 piece) 5,851 302
Soy sauce ramen (270 g) 5,377 476
Fried egg (2 pieces) 4,304 257
Fried potato (160 g) 4,099 448
Cream puff (1 piece) 3,799 123
Fried noodles (190 g) 3,628 512
Strawberry sponge cake (1 cut) 2,998 539
Toast with butter (1 piece) 2,447 259
Spaghetti with meat sauce (280 g) 2,063 616
Tofu with soy sauce (118 g) 624 73
Boiled egg (2 pieces) 382 211
Potato salad (140 g) 249 372
Miso soup (1 cup) 227 39
Raw egg (2 pieces) 164 211
Udon noodles (130 g) 71 339
Strawberry (120 g) 52 96
Banana (90 g) 51 78
Boiled spinach (30 g) 30 9
White rice (150 g) 16 252
Table 1. 
AGEs content in meals.
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Dalal et al. [6] found an association between elevated serum CML level and poor 
grip strength in 559 older women with physical disability (≥ 65 years old). A similar 
result was observed in the InCHIANTI study, which is a population-based prospec-
tive cohort study conducted in the Chianti region in Italy. The study showed that 
elevated plasma CML level was at high risk of slow walking speed (odds ratio 1.56, 
95% confidence interval 1.02–2.38, P = 0.04) in 944 older community-dwelling 
adults (≥ 65 years old) [7]. Sun et al. [9] also reported that elevated serum CML 
level was a risk factor for developing severe walking disability. In the study, which 
had a 30-month follow-up in 394 older women (≥ 65 years old), it was shown that 
compared with the group of lower three quartiles of CML, the patients in the group 
of highest quartile of CML were more likely to develop severe walking disability 
(hazard ratio 1.54, 95% confidence interval 1.04–2.29, P = 0.03). A community-
based cross-sectional study by Yang et al. [16] showed that urinary CML level was 
negatively associated with grip strength among 41 older women but not 63 older 
men (≥ 65 years old). Furthermore, the joint association of urinary CML level and 
mobility function was correlated with the risk of developing sarcopenia among 
older adults (odds ratio 13.76, 95% confidence interval 1.03–183.83, P < 0.05). In 
addition to CML, increased serum pentosidine, a well-known AGEs found in the 
plasma and tissues of diabetic and uremic subjects [40], was shown to be negatively 
associated with skeletal muscle mass in 133 postmenopausal women with type 
2 diabetes (mean age 66.8 years) [10] and in 70 elderly women with or without 
sarcopenia (≥ 53 years old) [17].
These findings are also supported by studies using non-invasive AGEs mea-
surement methods. Because several AGEs have characteristic fluorescence, the 
measurement of skin autofluorescence (SAF) is often adopted to assess the level 
of AGEs in the body. Momma et al. [8] investigated the relationship between SAF 
and muscle strength and power in 232 adult men (median age 46.0 years) and 
found that participants with higher SAF had lower grip strength and leg extension 
power. Kato et al. [11] also reported that SAF was significantly higher in the low 
skeletal muscle index group compared with the normal skeletal muscle index group 
among 132 elderly people (mean age 59.0 years). Moreover, SAF was shown to be an 
independent factor associated with low skeletal muscle index (odds ratio 15.7, 95% 
confidence interval 1.85–133.01, P = 0.012). The negative association between SAF 
and muscle mass (odds ratio 1.48, 95% confidence interval 1.23–1.78, P < 0.001), 
grip strength (odds ratio 1.98, P = 0.003), hip flexion strength (odds ratio 1.50, 
P = 0.012), and hip abduction strength (odds ratio 1.78, P = 0.001) was found 
among 9,203 participants (mean age 57.8 years) in the Nagahama study, which is a 
large-scale population-based cohort study in Japan [13]. Another large population-
based cohort study in the Netherlands, the Lifelines study also demonstrated the 
relationship between SAF and poor physical functioning among 5,624 participants 
(≥ 65 years old) [14]. In a study of diabetic patients, Mori et al. [12] reported that 
knee extension power was negatively correlated with SAF among 36 patients with 
type 1 diabetes (mean age 55.7 years). They subsequently reported that SAF was 
the independent determinant for skeletal muscle mass index (odds ratio 6.38, 
95% confidence interval 1.93–21.08, P < 0.05), grip strength (odds ratio 3.55, 95% 
confidence interval 1.57–8.00, P < 0.05), knee extension power (odds ratio 3.68, 
95% confidence interval 1.87–7.23, P < 0.05), and sarcopenia (odds ratio 7.73, 95% 
confidence interval 2.13–28.02, P < 0.05) among 166 patients with type 2 diabetes 
(mean age 63.2 years) [15]. Collectively, accumulation of AGEs may be a better pre-
dictor of skeletal muscle dysfunctions during aging process. Furthermore, recent 
our preliminary study found that SAF was negatively associated with leg extension 
power in 20 health young men (mean age 19.0 years) (Figure 2). Therefore, glyca-
tion stress may affect muscle strength even in young people, and it is considered 
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that grasping the glycation stress state not only from the elderly but also from the 
young age can contribute to the prevention of future muscle dysfunctions.
4.2 AGEs modification of contractile proteins in skeletal muscle
Decreased skeletal muscle quantity is deemed a crucial cause of aging-associ-
ated muscle dysfunctions. However, recent evidence suggests that the quality of 
muscle tissue is more functionally relevant than its quantity. Muscle contractile 
properties are identified as an important determinant of functional limitations 
in older adults [41]. In this context, several studies have focused on the effect 
of intracellular glycation on protein structure and function in skeletal muscle. 
Syrovy and Hodny [42] first reported in 1993 that incubation of myofibrils with 
ribose promoted the glycation of myofibrillar proteins such as myosin heavy 
chain, α-actinin, actin, and tropomyosin, accompanied by reduced ATPase activ-
ity. The decrease in ATPase activity associated with the glycation is supported by 
several subsequent studies [43–45]. A major component of skeletal muscle, myo-
sin contains 201 lysine residues and offers numerous potential sites for glycation. 
In fact, Ramamurthy et al. [46] demonstrated that glucose exposure to rodent 
skeletal muscle fiber induced myosin structural change and reduction of shorten-
ing velocity of myosin. The study is the first report to show the glycation-induced 
protein structural and functional changes in skeletal muscle. Furthermore, some 
researchers have found that actin and connective tissues were also modified with 
AGEs in skeletal muscle of old rats [47] and human [48]. Structural or chemical 
changes in actin, myosin, and extracellular matrix are likely to deteriorate muscle 
function by affecting actomyosin ATPase activity or stiffness [49, 50]. Our pre-
liminary experiment also found that 45 AGEs-modified proteins were increased 
in skeletal muscle of old mice (24-month age) compared with that of young adult 
mice (6-month age) (unpublished data). These intracellular or extracellular 
AGEs modifications of skeletal muscle proteins may be a potent factor of aging-
associated skeletal muscle dysfunctions.
Figure 2. 
Correlation between skin autofluorescence (SAF) and leg extension power. The subjects were 20 healthy young 
men, and after measuring the subcutaneous glycation state with an AGEs sensor (RQ-AG01J, Sharp Life 
Sciences, Hyogo, Japan), the maximum lift weight of leg extension was measured. Statistical significance was 
assessed using Pearson’s correlation.
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4.3 AGEs and insulin resistance in skeletal muscle
In skeletal muscle, the initial insulin signaling events include insulin binding 
to the extracellular α-subunit of the insulin receptor, rapid phosphorylation of the 
receptor (auto-phosphorylation) and insulin receptor substrate (IRS)-1 on tyrosine 
residues, and recruitment and activation of class IA phosphatidylinositol 3-kinase. 
These lead to the generation of the critical second messenger PI-3,4,5-triphosphate, 
which in turn triggers the activation of Akt [51]. TBC1 domain (TBC1D) family 
member 1 and TBC1D4 act as downstream mediators of Akt. TBC1D1 and TBC1D4 
contain a Rab-GTPase-activating protein domain that prevents glucose transporter 
4 (GLUT4) translocation by inactivating Rab proteins. TBC1D1 and TBC1D4 dis-
sociate from GLUT4 vesicles in the phosphorylated state, and thereby facilitating 
GLUT4 translocation and glucose transport [52, 53].
Many evidence have shown that AGEs impair insulin signaling transduction 
and induce insulin resistance in skeletal muscle. Miele et al. [54] showed that 
exposure of glycated albumin (0.1–0.2 mg/ml) to skeletal muscle cells for 24 hours 
impaired insulin-stimulated 2-deoxyglucose uptake, accompanied by reduced IRS-1 
tyrosine phosphorylation, Akt activity, but not insulin receptor kinase activity, 
suggesting that AGEs affect factors downstream from insulin receptor. AGEs-
induced inhibition of glucose transport was supported by the work of Wu et al. 
[55] that exposure of glyoxal-derived AGEs (0.1 mg/ml) to skeletal muscle cells for 
8–48 hours completely abolished 2-deoxyglucose uptake. Their subsequent research 
found that AGEs-induced impairment of insulin action might be mediated by the 
formation of multimolecular complex among RAGE/IRS-1/src and protein kinase 
C [56]. Animal study by Rai et al. [57] demonstrated that fructose intake (20% in 
drinking water) for 16 weeks decreased insulin-stimulated Akt phosphorylation 
accompanied by elevated serum and muscle AGEs level and RAGE mRNA level in 
rat skeletal muscle. However, these changes were suppressed by co-ingestion of 
AGEs inhibitor aminoguanidine (100 mg/kg). Pinto-Junior et al. [58] showed that 
injection of glycolaldehyde-derived AGEs (20 mg/kg/day) to rat for 12 weeks led to 
whole-body insulin resistance and decreased GLUT4 mRNA and protein levels in 
skeletal muscle. Furthermore, they demonstrated that exposure of glycolaldehyde-
derived AGEs (1.0 mg/ml) to skeletal muscle cells for 2.5 hours increased nuclear 
factor (NF)-κB expression and nuclear protein binding activity into a GLUT4 gene 
promoter NF-κB binding site, suggesting that AGEs reduce GLUT4 transcrip-
tion through NF-κB signaling. These AGEs-induced aggravating effect on insulin 
signaling may induce skeletal muscle insulin resistance, and thereby contributing to 
impairment of whole-body glucose homeostasis with aging or diabetes.
4.4 The effect of AGEs on myogenesis, development, atrophy of skeletal muscle
As described above, AGEs are a crucial factor affecting skeletal muscle func-
tions, especially skeletal muscle mass. Considering the formation process of AGEs 
derived from sugar, it has been initially investigated the effects of AGEs on diabetic 
muscle atrophy. Snow et al. [59] observed distribution patterns of AGEs in skeletal 
muscle of diabetic rats and found the presence of CML intracellularly and at sites 
along the muscle fiber periphery. However, there was no difference in muscle fiber 
cross-sectional area between AGEs-positive and -negative fibers in both control 
and diabetic rats, indicating the indirect effect of intracellular AGEs on muscle 
size. Alternatively, a more detailed study by Chiu et al. [60] demonstrated that 
decreased muscle mass and fiber cross-sectional area in diabetic rats was attenuated 
by the 4-week treatment with AGEs inhibitor, alagebrium chloride, accompanied by 
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decreased AGEs and RAGE expressions. They also investigated the direct effect of 
AGEs on muscle atrophy and found that exposure of glucose-derived AGEs (0.025–
0.2 mg/ml) to human primary skeletal muscle cells for 48 hours induced myotube 
atrophy via RAGE, 5’AMP-activated protein kinase, and Akt signaling-mediated 
upregulation of ubiquitin-proteasome system.
Our recent study supports the involvement of RAGE in skeletal muscle atrophy. 
In addition to diabetes, muscle disuse due to injury, casting, and bedrest is a potent 
inducer of muscle mass loss [61]. However, there was no evidence that glycation 
stress was involved in disuse-induced skeletal muscle atrophy. Therefore, we inves-
tigated the contribution of RAGE to disuse-induced skeletal muscle atrophy [62]. 
Our study showed that 1-week hindlimb suspension procedure to mice led to muscle 
atrophy accompanied by intracellular MG-H1 and CML accumulations. However, 
treatment with RAGE antagonist during the suspension attenuated the atrophic 
response (Figure 3), and muscle mass inversely correlated with the accumulation 
of MG-H1 and CML in skeletal muscle (Figure 4). RAGE inhibition also suppressed 
the atrophy-associated expression of proinflammatory cytokines and activation of 
ubiquitin-proteasome system. These findings suggest the contribution of RAGE to 
Figure 3. 
Soleus weight normalized to body weight and muscle fiber cross sectional area (CSA) after hindlimb 
suspension and/or receptor for AGEs (RAGE) antagonist treatment. Mice in the HS group were subjected to 
continuous hindlimb suspension for 1 week. Age-matched mice that did not undergo hindlimb suspension were 
used as controls (CON). Mice in the HS + FPS-ZM1 group were injected daily intraperitoneally with 1 mg/kg 
FPS-ZM1, a RAGE antagonist, during hindlimb suspension. Data are expressed as means ± SE; n = 7–9 per 
group. Individual data points are indicated on the bar graph. Representative images of immunofluorescence 
are shown. Scale bars, 50 μm. The value of effect size is listed in parentheses. Statistical significance was 
analyzed using Tukey–Kramer multiple comparison tests. This figure was adapted from Egawa et al. [62] with 
permission from the publisher.
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disuse-induced skeletal muscle atrophy. Furthermore, in this study, RAGE expres-
sion was increased in response to suspension, and this was limited to atrophied 
soleus and plantaris muscles but not unatrophied extensor digitorum longus 
muscle. Therefore, muscle disuse itself but not systemic mediators may regulate 
RAGE expression.
The effect of glycation stress on muscle growth was first reported in our research 
[63]. We evaluated the differences in muscle mass, contractile properties and 
molecular responses between mice that received a diet containing high-AGEs and 
low-AGEs for 16 weeks [63]. As a result, exposure to a high-AGEs promoted CML 
accumulation in skeletal muscle, suppressed muscle growth, and induced skeletal 
muscle dysfunctions including suppression of muscle strength, fatigue resistance, 
and force production (Figure 5). In addition, the expression of myogenic factors 
and phosphorylation of p70 s6 kinase, an enzyme playing a key role in the regulation 
of protein synthesis, were decreased in the high-AGEs treated group. These results 
suggest that exposure to AGEs impairs postnatal growth and muscle development.
To clarify the underlying mechanism of AGEs-induced inhibition of muscle 
growth, we next carried out the comprehensive analysis of protein phosphoryla-
tion status by using the reverse phase protein array method [64]. In the study, the 
average level of phosphorylation of skeletal muscle cells exposed to various kinds of 
AGEs (glyoxylic-, pyruvate, glycolaldehyde, and glucose-derived AGEs, 0.1 mg/ml) 
was increased at eight phosphorylation sites and decreased at 64. The most upregu-
lated phosphorylation sites were signal transducer and activator of transcription 3 
(STAT3) Tyr705. The most downregulated phosphorylation sites were extracellular 
signal-regulated kinase (ERK) Thr202/Tyr204. Almost all of the phosphorylation 
sites related to insulin/insulin-like growth factor 1 (IGF-1) signaling were also 
downregulated by AGEs (Figure 6). Increased STAT3 Tyr705 phosphorylation and 
decreased ERK Thr202/Tyr204 phosphorylation were also confirmed in the skeletal 
muscles of mice treated with a diet high in AGEs for 16 weeks. These results suggest 
that systemic AGEs modulate cellular signaling transduction pathways, such as 
STAT3 and insulin/IGF-1 signaling, and thereby contribute to the impairment of 
skeletal muscle growth and development. Accordingly, Adachi et al. demonstrated 
that IGF-1 treatment protected AGEs-induced deterioration of myogenic differen-
tiation in skeletal muscle cells [65].
Figure 4. 
The correlation between methylglyoxal (MG)- or Nε-(carboxymethyl) lysine (CML)-modified protein level 
and muscle weight. For the quantification of MG-modified and CML-modified proteins, the signal intensity 
of full-molecular-weight was quantified after western blotting. n = 8 per group. Statistical significance was 
assessed using Pearson’s correlation. This figure was adapted from Egawa et al. [62] with permission from the 
publisher.
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5.  Therapeutic perspectives for AGEs-induced skeletal muscle 
dysfunctions
AGEs-RAGE axis seems to be the most contributor to skeletal muscle dysfunctions 
under glycation stress condition [66]. Recently, Chiappalupi et al. [67] demonstrated that 
cancer cachexia-induced muscle wasting and inflammatory responses were prevented 
in RAGE-null mice. In this regard, several RAGE antagonists were used for preclinical 
and clinical studies [68, 69]. For example, FPS-ZM1, which was identified by screening 
5,000 compounds for their ability to inhibit RAGE and amyloid-β interaction, can block 
amyloid-β-induced cellular stress [70]. Azeliragon, which is an orally-active small-mol-
ecule antagonist of RAGE, improves cognitive function in Alzheimer disease patients by 
inhibiting inflammation and amyloid-β accumulation [71]. As our study showed, RAGE 
inhibition by FPS-ZM1 could prevent disuse-induced muscle atrophy [62]. Potentially, 
these RAGE inhibitors might be useful for various skeletal muscle atrophy.
Figure 5. 
The grip strength test, wire-hanging test, and in vitro force production of plantaris muscles in mice fed a diet 
low in AGEs (L-AGEs) or a diet high in AGEs (H-AGEs). The grip strength test and wire-hanging test was 
conducted 5 and 4 days before the end of the 16-week study, respectively. For measuring in vitro forth production, 
isolated plantaris muscle was allowed to rest for 30 min and the muscle was tetanically contracted at frequencies 
of 0, 5, 10, 25, 50, 75, and 100 Hz with a 2 min rest between contractions. Data are expressed as mean ± SE, n = 10 
per group. *P < 0.05 vs. L-AGEs mice. Statistical significance was analyzed using Student’s t test or Tukey–Kramer 
multiple comparisons tests. This figure was adapted from Egawa et al. [63] with permission from the publisher.
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Figure 6. 
The phosphoproteins related to insulin/insulin-like growth factor-1 (IGF-1) signaling. C2C12 myotubes 
on day 4 of differentiation were incubated with glyoxylic acid-derived AGEs, pyruvate- derived AGEs, 
glycolaldehyde- derived AGEs, glucose- derived AGEs, or BSA at 0.1 mg/mL for 24 h. After that, reverse 
phase protein array analysis was performed. The phosphoproteins related to insulin/IGF-1 signaling are 
represented as the relative log fold-change (FC) values. This figure was adapted from Egawa et al. [64] with 
permission from the publisher. IRS-1, insulin receptor substrate-1; IGF-1, insulin-like growth factor-1; GSK, 
glycogen synthase kinase; mTOR, mammalian target of rapamycin; 4E-BP1, eukaryotic translation initiation 
factor 4E binding protein- 1; eIF, eukaryotic translation initiation factor; eEF2k, eukaryotic elongation 
factor- 2 kinase.
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Plant-derived phytochemicals are also potentially beneficial for maintaining 
muscle functions. Screening of 536 kinds of plants has confirmed anti-glycation 
activity in more than 100 kinds of materials [72]. Recent our study [73] found that 
propolis, a natural resinous substance produced by honeybees, has an inhibitory 
effect on AGEs formation. Furthermore, propolis intake (0.1%-containing diet) for 
20 weeks under glycation stress conditions from methylglyoxal exposure prevented 
intracellular MG-H1 accumulation and inflammatory cytokine expressions in 
mouse skeletal muscle (Figure 7).
In addition to phytochemicals, organic compound with anti-glycation effect, 
pyridoxamine has been shown to inhibit diabetes-related muscle dysfunctions. 
Muellenbach et al. [74] first showed that treatment with pyridoxamine (60 mg/kg i.p. 
injection) for 6 weeks improved insulin-stimulated glucose transport in the skeletal 
muscle of obese Zucker rats. In a study by Hagiwara et al. [75] using a high-fat diet 
fed rats, it was shown that 12-week treatment with pyridoxamine (300 mg/kg/day in 
drinking water) attenuated reductions in Akt phosphorylation and GLUT4 expres-
sion in the plasma membrane of skeletal muscle. Mastrocola et al. [76] demonstrated 
that pyridoxamine treatment to rats fed a high-fructose diet (60% of calories) for 
12 weeks suppressed CML accumulation, RAGE upregulation, sirtuin-1 reduction, 
mitochondrial dysfunction, and contractile dysfunction in skeletal muscle. These 
Figure 7. 
The content of methylglyoxal (MGO)-derived AGEs and mRNA expression of interleukin (IL)-1β, IL-6, toll-
like receptor 4 (TLR4), and receptor for AGEs (RAGE) in the extensor digitorum longus muscles. The muscles 
were dissected from mice treated with or without propolis (0.1%)-containing diet or MGO (0.1%)-containing 
drinking water for 20 weeks. Data are expressed as means ± SE; n = 3–6 per group. * P < 0.05 between the 
groups. Statistical significance was analyzed using Tukey–Kramer multiple comparisons tests. This figure was 
adapted from Egawa et al. [73] with permission from the publisher.
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results suggest that even in situations where glycation stress increase such as high-
AGEs diet intake, skeletal muscle dysfunctions can be prevented by simultaneously 
ingesting compounds and foods that have anti-glycation effects.
6. Conclusion
Glycation stress is a potential factor that reduces physical functions, which 
has become attention in recent years as well as oxidative stress. Glycation stress is 
mainly caused by intracellular AGEs formation and accumulation in the body, and 
also by ingestion from food products. Exposure to AGEs on skeletal muscle cells 
leads to skeletal muscle dysfunctions including reductions of mass, contractile 
function, insulin sensitivity. These dysfunctions seem to be attributed to RAGE-
induced inflammatory responses and deteriorations of cellular signaling transduc-
tion, including insulin/IGF-1 signaling. However, some therapeutic strategies, such 
as treatment with RAGE antagonists, AGEs inhibitors, phytochemicals can over-
come the aggravating effects. Glycation research on skeletal muscle has not been 
sufficiently carried out, and further studies in the future, especially the elucidation 
of the effect of glycation stress on skeletal muscle and its underlying molecular 
mechanism, and the development of strategies on preventing the accumulation of 
AGEs in skeletal muscle, are desired.
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